Table 5.
Anti-malarial prescription practice in both study arms showing the frequency of use of different ACT and non-ACT drugs within each study group
| Antimalarial dispensed | Intervention pharmacy (frequency and % antimalarials within study arm) n = 360 | Control pharmacy (frequency and % antimalarials within study arm) n = 607 |
|---|---|---|
| Artemether-Lumefantrine |
180 |
337 |
| (50.0%) |
(55.5%) |
|
| Artesunate-Amodiaquine |
42 |
47 |
| (11.7%) |
(7.7%) |
|
| Dihydroartemisinin-Piperaquine |
30 |
33 |
| (8.3%) |
(5.4%) |
|
| Artesunate-Sulfadoxine-Pyrimethamine |
8 |
12 |
| (2.2%) |
(2.0%) |
|
| ACT (total) |
260 |
429 |
| (72.2%) |
(70.6%) |
|
| Sulfadoxine-Pyrimethamine alone |
39 |
75 |
| (10.8%) |
(12.4%) |
|
| Artesunate alone |
47 |
58 |
| (13.1%) |
(9.6%) |
|
| Chloroquine alone |
13 |
30 |
| (3.6%) |
(4.9%) |
|
| Quinine alone |
1 |
15 |
| (0.3%) |
(2.5%) |
|
| Non-ACT (total) | 100 |
178 |
| (27.8%) | (29.4%) |